Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 53 | 47 | 42 | 43 | 39 |
| Accounts receivable | -72 | -37 | 57 | 161 | 1 |
| Other Working Capital | -193 | -195 | 424 | 336 | -561 |
| Other Operating Activity | -962 | -1,099 | -1,590 | -1,526 | -1,214 |
| Operating Cash Flow | $-1,174 | $-1,284 | $-1,067 | $-986 | $-1,735 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -12 | -2 | -32 | -46 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 1 |
| Investing Cash Flow | $-9 | $-12 | $-2 | $-32 | $-45 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -10 | -8 | -1 | -3 | -7 |
| Common Stock Issued | 6 | 998 | 1,591 | 310 | 1,379 |
| Other Financing Activity | 2,276 | 72 | 0 | 603 | -1,195 |
| Financing Cash Flow | $2,272 | $1,062 | $1,590 | $910 | $177 |
| Exchange Rate Effect | 66 | -11 | 119 | -4 | -220 |
| Beginning Cash Position | 983 | 1,228 | 588 | 700 | 2,523 |
| End Cash Position | 2,138 | 983 | 1,228 | 588 | 700 |
| Net Cash Flow | $1,089 | $-234 | $521 | $-108 | $-1,603 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,174 | -1,284 | -1,067 | -986 | -1,735 |
| Capital Expenditure | -9 | -12 | -2 | -32 | -46 |
| Free Cash Flow | -1,183 | -1,296 | -1,069 | -1,018 | -1,781 |